Rockville, MD (PRWEB) January 22, 2014
Opportunity Analyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017
Given the Significant Unmet Needs in this Market, Several Opportunities Remain for Novel Therapies
One opportunity includes thrombolytics that can be administered beyond nine hours. Although desmoteplase will have a potential extended therapeutic time window of nine hours, enabling a greater proportion of patients to be eligible for thrombolysis, there is ample opportunity for an effective and safe therapy that can be given after nine hours post-stroke onset.
Acute Ischemic Stroke (AIS) patients are still awaiting approval of the first effective neuroprotective therapies, and given the lack of Phase III neuroprotective agents, GlobalData does not expect any neuroprotective agents to launch within the five-year forecast period. With the absence of such a product in the AIS treatment paradigm, an approved first-in-class neuroprotective agent is likely to gain rapid patient uptake.
Novel neurorestorative therapies - although much progress has been made in the clinical management of stroke, for example in the form of next-generation thrombolytic agents such as desmoteplase, there are still limited treatment options to restore lost function once neuronal death has already occurred.
To order this report: Opportunity Analyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017
Contact: Shauna 800.298.5699 Customerservice(at)marketresearch(dot)com
GlobalData
GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
Link:
Opportunity Analyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017